Sight Sciences (NASDAQ:SGHT) CEO Sells $148,036.44 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 22,362 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $6.62, for a total value of $148,036.44. Following the transaction, the chief executive officer owned 6,025,840 shares in the company, valued at $39,891,060.80. This trade represents a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Paul Badawi also recently made the following trade(s):

• On Tuesday, January 6th, Paul Badawi sold 11,870 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $88,787.60.
• On Friday, January 2nd, Paul Badawi sold 25,356 shares of Sight Sciences stock. The shares were sold at an average price of $7.43, for a total transaction of $188,395.08.

Sight Sciences Price Performance

SGHT opened at $6.02 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. The stock has a market capitalization of $318.28 million, a PE ratio of -6.69 and a beta of 2.42. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $9.24. The company’s 50 day simple moving average is $7.75 and its 200 day simple moving average is $5.36.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.10. The company had revenue of $19.91 million during the quarter, compared to analysts’ expectations of $17.74 million. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. As a group, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Piper Sandler set a $9.00 target price on shares of Sight Sciences in a report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Morgan Stanley increased their target price on Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Citigroup boosted their price target on Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Finally, UBS Group increased their price objective on shares of Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Sight Sciences has a consensus rating of “Hold” and an average price target of $8.30.

Institutional Investors Weigh In On Sight Sciences

A number of hedge funds have recently bought and sold shares of SGHT. AQR Capital Management LLC purchased a new stake in Sight Sciences during the 1st quarter worth approximately $128,000. Strs Ohio bought a new stake in shares of Sight Sciences in the first quarter worth $158,000. Rhumbline Advisers raised its holdings in Sight Sciences by 9.5% in the first quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock valued at $120,000 after acquiring an additional 4,319 shares in the last quarter. Palumbo Wealth Management LLC bought a new position in Sight Sciences during the 2nd quarter valued at $328,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in Sight Sciences by 38.9% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock worth $66,000 after acquiring an additional 4,453 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.